Oxford Biomedica shares rise on post-acquisition guidance
5th Mar 2024 16:22
(Sharecast News) - Shares in cell and gene therapy specialist Oxford Biomedica were jumping on Tuesday afternoon, after the company updated the market on its medium-term financial guidance.
Read moreDirector dealings: TUI, Oxford Biomedica board members linked to buys
27th Sep 2023 11:24
(Sharecast News) - TUI was among those on the list of director buys on Wednesday after its chief executive officer purchased almost 50,000 shares.
Read moreLiberum cuts target price for Oxford Biomedica, saying it still lacks sufficient scale
28th Nov 2022 11:43
(Sharecast News) - Analysts at Liberum cut their target price for shares Oxford Biomedica arguing that the company's pan-vector offering had yet to reach sufficient scale in order to deliver sustainable profitability.
Read moreOxford Biomedica taps Frank Mathias as its new CEO
22nd Nov 2022 09:30
(Sharecast News) - Gene and cell therapy specialist Oxford Biomedica announced the appointment of Dr Frank Mathias as its new chief executive officer and a board director on Tuesday, effective from March.
Read moreOxford Biomedica swings to loss as Covid vaccine winds down
15th Sep 2022 10:27
(Sharecast News) - Oxford Biomedica reported a 21% decrease in its first-half total revenue on Thursday, to £64m.
Read moreOxford Biomedica inks LSA with new US biotech partner
7th Sep 2022 07:42
(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck a new licence and supply agreement with an unnamed US partner.
Read moreOxford Biomedica inks LSA with US biotech firm, launches new project with Orchard Therapeutics
26th Jul 2022 08:44
(Sharecast News) - Gene and cell therapy group Oxford Biomedica inked a new licence and supply agreement with an unnamed US private biotechnology on Tuesday company and also launched a new project with Orchard Therapeutics.
Read moreOxford Biomedica signs new Covid vaccine deal with AstraZeneca
1st Jul 2022 07:03
(Sharecast News) - Oxford Biomedica has signed a new three-year deal to make AstraZeneca's Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.
Read moreOxford Biomedica sees FDA lift clinical hold on Homology's HMI-102 trial
14th Jun 2022 09:35
(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Tuesday that the US Food and Drug Administration had notified Homology Medicines that the clinical hold on its pheNIX gene therapy trial of HMI-102 in adults with phenylketonuria had been lifted.
Read moreOxford Biomedica reports year of solid growth
20th Apr 2022 09:10
(Sharecast News) - Oxford Biomedica reported a 63% improvement in total revenues in its preliminary results on Wednesday, to £142.8m, although its outlook was somewhat less rosy amid a pause in vaccine manufacturing.
Read moreOxford Biomedica's Parkinson's licensee pulls out
1st Feb 2022 07:40
(Sharecast News) - Oxford Biomedica's licensee for a Parkinson's disease treatment has pulled out of development and returned the rights to the UK company.
Read moreOxford Biomedica creates venture with Homology, launches £80m fundraise
28th Jan 2022 09:56
(Sharecast News) - Cell and gene therapy specialist Oxford Biomedica announced an agreement with Homology Medicines on Friday, as well as a placing to raise £80m from new and existing shareholders, including a retail offer through the PrimaryBid platform.
Read moreOxford Biomedica CEO John Dawson to step down
17th Jan 2022 07:10
(Sharecast News) - Oxford Biomedica chief executive John Dawson said he was stepping down after 13 years at the helm of the Gene and cell therapy firm which helped develop a Covid-19 vaccine with AstraZeneca.
Read moreOxford Biomedica signs licence, supply deal with Cabaletta Bio
5th Jan 2022 07:29
(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
Read moreOxford Biomedica strikes new license and supply agreements
13th Dec 2021 07:31
(Sharecast News) - Gene and cell therapy group Oxford Biomedica has struck new license and supply agreements for its lentiviral vectors.
Read more